Journal
ONCOGENE
Volume 31, Issue 14, Pages 1794-1803Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2011.371
Keywords
Pim1 kinase; MYC; gene expression; Erk; tumorigenicity
Funding
- NCI [RO1CA123484, R01CA152601]
- DOD [BC093803]
Ask authors/readers for more resources
PIM1 kinase and MYC are commonly co-expressed in human prostate cancer and synergize to induce rapidly progressing prostate cancer in mouse models. Deficiency of the Pim kinase genes is well tolerated in vivo, suggesting that PIM1 inhibition might offer an attractive therapeutic modality for prostate cancer, particularly for MYC-expressing tumors. Here we examine the molecular consequences of Pim1 and MYC overexpression in the prostate as well as the effects of depleting Pim1 in prostate carcinoma cells with high levels of MYC. Overexpression of Pim1 in the mouse prostate induces several pro-tumorigenic genetic programs including cell cycle genes and Myc regulated genes before the induction of any discernible pathology. Pim1 depletion by RNA interference in mouse and human prostate cancer cells decreased cellular proliferation, survival, Erk signaling and tumorigenicity even when MYC levels were not significantly altered. These results indicate that PIM1 may be necessary to maintain tumorigenicity, and further support efforts aimed at developing PIM1 inhibitors for prostate cancer therapy. Oncogene (2012) 31, 1794-1803; doi: 10.1038/onc.2011.371; published online 22 August 2011
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available